NK92/NK92/NK92/人恶性非霍奇金淋巴瘤患者的自然

NK92/NK92细胞系/NK92细胞株/NK92人恶性非霍奇金淋巴瘤患者的自然杀伤细胞

Cell line name NK-92

Synonyms NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK

Accession CVCL_2142

Resource Identification Initiative To cite this cell line use: NK-92 (RRID:CVCL_2142)

Comments Group: Patented cell line.

Part of: LL-100 blood cancer cell line panel.

Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670.

Population: Caucasian.

Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.

Characteristics: IL2 dependent.

Characteristics: Does not express FCGR3A/CD16.

Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488).

Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).

Omics: Deep exome analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: Natural killer cell; CL=CL_0000623.

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

 

PubMed=11454312; DOI=10.1089/152581601750288975

Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

J. Hematother. Stem Cell Res. 10:369-383(2001)

 

PubMed=12850795; DOI=10.1080/14653240310001523

Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.

Cytotherapy 5:259-272(2003)

 

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954

Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.

Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.

Cancer Sci. 97:605-610(2006)

 

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560

Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M.

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

J. Immunol. 180:6392-6401(2008)

 

PubMed=19194464; DOI=10.1038/leu.2009.3

Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H., Klinkebiel D.L., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.

Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.

Leukemia 23:1139-1151(2009)

 

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

 

PubMed=21052088; DOI=10.1038/leu.2010.255

Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.-Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K.E., Vose J.M., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.

International Peripheral T-cell Lymphoma Project

Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.

Leukemia 25:348-358(2011)

 

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010

Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M.

Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.

Mol. Immunol. 48:1512-1517(2011)

 

PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911

Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A., Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K., de Leval L., McKeithan T.W., Chan W.-C.

Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.

Nat. Commun. 6:6025.1-6025.12(2015)

 

PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582

Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Cancer Immunol. Immunother. 65:485-492(2016)

 

PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623

Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E., Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.

Genome-wide analyses and functional profiling of human NK cell lines.

Mol. Immunol. 115:64-75(2019)